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OBJECTIVES: To compare the sensitivity to change of the
Hamilton Depression Rating Scale (HAMD) and the
Montgomery-Åsberg Depression Rating Scale (MADRS) as
outcome measures in antidepressant randomised controlled trials
(RCTs). METHODS: Data come from 2 RCTs (studies A and B)
which assessed the efﬁcacy of SSRIs plus pindolol or plus placebo
in patients with Major Depression (MD). Study B recruited treat-
ment resistant patients. Both studies included the HAMD and the
MADRS as outcome measures. Study A did 10 follow-up mea-
surements (since day 0 to day 42). Study B did 3 follow-up
measurements (since day 0 to day 10). Standardised estimates for
the change in the severity of depression since day 0 were calcu-
lated by a within-group effect size (dw) which accounted for the
correlation between measurement times. RESULTS: Study A
showed a decreasing curvilinear pattern for the HAMD effect
sizes (0, -0.55, -0.96, -1.25, -1.53, -1.97, -2.27, -2.15, -2.41,
-2.57) which overlapped perfectly with the MADRS estimates
(0, -0.56, -0.95, -1.23, -1.56, -1.88, -2.13, -2.17, -2.45,
-2.64). Similar pattern was obtained in study B (HAMD: 0,
-0.32, -0.62; MADRS: 0, -0.22, -0.52). Additionally, our esti-
mates point to a reliable decrease of the severity of depression
even since the ﬁrst post-baseline measurement (study A, HAMD
dw = -0.55 [95% CI = -0.73 to -0.37], MADRS dw = -0.56
[95% CI = -0.74 to -0.38]; study B, HAMD dw = -0.32 [95%
CI = -0.52 to -0.11], MADRS dw = -0.22 [95% CI = -0.39 to
-0.05]). CONCLUSION: Contrary to common beliefs, the
HAMD shows an indistinguishable pattern of change from the
one obtained with the MADRS, either in common MD popula-
tions (study A), or in treatment resistant patients (study B). Also,
reliable symptomatic changes seem to appear early on in the
course of an antidepressant treatment.
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OBJECTIVES: Investigate the impact of paliperidone extended-
release tablets (paliperidone ER), a newly available oral anti-
psychotic agent, on a health care formulary from a payer’s
perspective using a hybrid cost-effectiveness/budget impact
approach. METHODS: An atypical oral antipsychotic formulary
containing risperidone, olanzapine, aripiprazole, quetiapine and
ziprasidone was compared to a formulary including the same 5
oral atypicals with the addition of paliperidone ER. Total
medical costs and number of re-hospitalization stays were
derived from Pharmetrics, a US outpatient insurance claims data-
base with regionally representative coverage. Patients diagnosed
with schizophrenia (ICD-9-CM code) in the year prior to initi-
ating a new antipsychotic treatment with 1 full year retrospective
and prospective data between January 2002-March 2005 were
included. Marketshare was based on IMS Health NDTI MAT
ending June 2006. Paliperidone ER was assumed to attain 10%
utilization, comparable to latest market entrant. Costs included
all schizophrenia-related inpatient and outpatient costs, and
re-hospitalization stays in the one year following initiation of
treatment. Treatment effect was quantiﬁed by adjusting observed
values for each atypical for potential confounders including
patient characteristics, prior hospitalizations and co-morbidity
using generalized gamma regression (GLM). The adjusted out-
comes of risperidone and olanzapine were used to simulate the
costs and effects of paliperidone ER. Sensitivity analyses were
performed on key assumptions and nonparametric bootstrapping
was applied to observed data. RESULTS: An estimated $121 per
patient in total annual medical cost savings (95% CI: 35.11–
206.27) could be achieved with the addition of paliperidone ER
to the formulary. Assuming a hypothetical cohort of 10,000
patients, this translates into yearly savings of $1.2 million. CON-
CLUSION: The addition of a new agent with similar efﬁcacy and
tolerability proﬁle as paliperidone ER, may lead to a more cost-
effective formulary.
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OBJECTIVES: The existence of somatic and psychiatric comor-
bidity among patients with depressive disorder is well-known
and may inﬂuence estimates of health-related quality of life
(HrQoL) in depression. This study reports on the effect of comor-
bidity on self-reported EQ-5D in the general population.
METHODS: Data from the US Medical Expenditures Panel
Study (MEPS) 2003 was used. A weighted linear regression
model was constructed to allow for its complex sampling design.
Socio-economic covariates were included in the model, dichoto-
mized (any diagnosis vs no diagnosis) comorbidity variables
based on ICD-9 chapters were then added. The effects of major
chronic diseases were analyzed separately as comorbidity vari-
ables. Separate models were constructed for men and women.
RESULTS: The EQ-5Dindex adjusted for age and depression was
0.902 for men and 0.887 for women; depression had a disutility
of 0.257 for men and 0.207 for women. Adding socio-economic
covariates yielded a value for EQ-5D of 0.978 and 0.987 respec-
tively, the disutility of depression decreased to 0.246 for men and
0.172 for women. Among disease conditions that contributed
signiﬁcantly to the estimate of EQ-5D and disutility for depres-
sion in both genders were other psychiatric conditions, diabetes,
migraine and other neurologic conditions, cardiovascular disease
and musculoskeletal diseases. For women only, ischaemic heart
disease inﬂuenced the model signiﬁcantly while thyroid diseases
had a signiﬁcant inﬂuence for men only. The ﬁnal disutility of
depression in the model was 0.154 for men and 0.115 for
women. CONCLUSION: A generalized estimate of the disutility
of depression in the population for use in pharmacoeconomic
studies may be difﬁcult to obtain due to the somatic and psy-
chiatric comorbidity in these patients. The comorbidity has a
signiﬁcant inﬂuence on the population disutility estimate for
depression.
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